Stock ALBPS BIOPHYTIS S.A.
Add to a list
To use this feature you must be a member
Log inSign up

Biophytis S.A. Stock

Equities

ALBPS

FR0012816825

Biotechnology & Medical Research

Market Closed - Euronext Paris
Other stock markets
 11:35:28 2024-04-26 am EDT 		5-day change 1st Jan Change
0.0023 EUR +4.55% Intraday chart for Biophytis S.A. -4.17% -54.90%
Apr. 25 European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Thursday Trading MT
Apr. 25 Top Premarket Decliners MT

Financials

Sales 2024 * 4.6M 4.92M Sales 2025 * 18.2M 19.46M Capitalization 2.63M 2.81M
Net income 2024 * -17M -18.18M Net income 2025 * -8M -8.55M EV / Sales 2024 * 0.57 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 0.14 x
P/E ratio 2024 *
-
P/E ratio 2025 *
-
Employees 22
Yield 2024 *
-
Yield 2025 *
-
Free-Float 40.58%
More Fundamentals * Assessed data

Chart Biophytis S.A.

Dynamic Chart

Latest news about Biophytis S.A.

European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Thursday Trading MT
Top Premarket Decliners MT
Biophytis S.A.(OTCPK:BPTS.Y) dropped from NASDAQ Composite Index CI
European Equities Traded in the US as American Depositary Receipts Jump in Tuesday Trading MT
European Equities Traded in the US as American Depositary Receipts Rebound in Monday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading But End Week Down MT
Biophytis Changes ADR Ratio From 100 to 4,000 Shares MT
Biophytis SA Announces Formation of New Scientific Advisory Board for Its Phase 2 OBA Clinical Study in Obesity CI
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading MT
European Equities Traded in the US as American Depositary Receipts Lower in Tuesday Trading MT
French Biotech Biophytis Files Patent Application for BIO101 MT
European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading MT
Biophytis S.A. Files a Patent Application in the Treatment of Obesity CI
Biophytis: patent application filed in the field of obesity CF
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading MT
More news

Analyst Recommendations on Biophytis S.A.

HC Wainwright Reiterates Biophytis at Buy With $15 Price Target MT
Traders Digest Jobless Claims Data After Fed Rate Hike, Prompting Mixed Premarket Trading for US Equity Futures MT
US Futures Lower Following Rate Hike, Ahead of Jobless, PMI Data MT
BIOPHYTIS : HC Wainwright Starts Biophytis SA at Buy With $15 Price Target MT
More recommendations

Press releases Biophytis S.A.

Biophytis S A : Announces Transfer of ADSs to OTC Market PU
Biophytis S A : Press Release PU
Biophytis S A : announces new Scientific Advisory Board for its phase 2 OBA clinical study in obesity PU
Biophytis S A : annonce la création d'un Conseil Scientifique pour son étude clinique de phase 2 OBA dans l'obésité PU
Biophytis S A : Press Release PU
More press releases

News in other languages on Biophytis S.A.

Biophytis S A : Communique de Presse
Biophytis S A : Communique de Presse
Biophytis : une demande de brevet déposée dans l'obésité
Biophytis S A : investit le marché de l'obésité
Biophytis S A : Communique de Presse
More news

Quotes and Performance

1 day+4.55%
1 week-4.17%
Current month-34.29%
1 month-32.35%
3 months-54.00%
6 months-72.62%
Current year-54.90%
More quotes

Highs and lows

1 week
0.00
Extreme 0.0021
0.00
1 month
0.00
Extreme 0.0021
0.00
Current year
0.00
Extreme 0.0021
0.01
1 year
0.00
Extreme 0.0021
0.03
3 years
0.00
Extreme 0.0021
1.20
5 years
0.00
Extreme 0.0021
2.73
10 years
0.00
Extreme 0.0021
19.30
More quotes

Managers and Directors - Biophytis S.A.

Managers TitleAgeSince
Stanislas Veillet CEO
 Chief Executive Officer 58 06-09-14
Nicolas Fellmann DFI
 Director of Finance/CFO 55 23-05-21
Claudia Ferreira CTO
 Chief Tech/Sci/R&D Officer - 23-09-13
Members of the board TitleAgeSince
Nadine Coulm BRD
 Director/Board Member 61 15-05-21
Claude Allary BRD
 Director/Board Member 69 21-07-06
Stanislas Veillet CEO
 Chief Executive Officer 58 06-09-14
More insiders

Quotes

Date Price Change Volume
24-04-26 0.0023 +4.55% 9,831,861
24-04-25 0.0022 -4.35% 34,726,470
24-04-24 0.0023 -8.00% 8,951,692
24-04-23 0.0025 +8.70% 23,554,760
24-04-22 0.0023 -4.17% 7,563,554

Real-time Euronext Paris, April 26, 2024 at 11:35 am EDT

More quotes

Company Profile

Biophytis S.A. is a biotechnology company in the clinical stage specialized in the development of drug candidates to slow degenerative processes and improve functional capacity in patients with age-related diseases, including respiratory failure in patients suffering from COVID-19. The company is located in Paris, France and Cambridge, Massachusetts.
Sector
Biotechnology & Medical Research
Calendar
2024-10-28 - Q2 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
BIOPHYTIS S.A. Stock Biophytis S.A.
-54.90% 2.81M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.74B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. ALBPS Stock